Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.

Errasti P, Izquierdo D, Martín P, Errasti M, Slon F, Romero A, Lavilla FJ.

Transplant Proc. 2010 Oct;42(8):3053-4. doi: 10.1016/j.transproceed.2010.07.066.

PMID:
20970608
2.

Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.

Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.

Transplant Proc. 2010 Oct;42(8):3050-2. doi: 10.1016/j.transproceed.2010.07.083.

PMID:
20970607
3.

Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.

Rodríguez-Moreno A, Ridao N, García-Ledesma P, Calvo N, Pérez-Flores I, Marques M, Barrientos A, Sánchez-Fructuoso AI.

Transplant Proc. 2009 Jul-Aug;41(6):2163-5. doi: 10.1016/j.transproceed.2009.06.003.

PMID:
19715862
4.

Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.

Sola E, Lopez V, Gutierrez C, Cabello M, Burgos D, Molina MG, Hernandez D.

Transplant Proc. 2010 Oct;42(8):2859-60. doi: 10.1016/j.transproceed.2010.07.062.

PMID:
20970551
5.

Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.

Kacar S, Gurkan A, Karaca C, Varılsuha C, Tilif S.

Transplant Proc. 2010 Nov;42(9):3513-6. doi: 10.1016/j.transproceed.2010.08.043.

PMID:
21094806
6.

Treatment with everolimus is associated with a procoagulant state.

Baas MC, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ.

Thromb Res. 2013 Aug;132(2):307-11. doi: 10.1016/j.thromres.2013.07.004. Epub 2013 Jul 29.

PMID:
23906938
7.

Timing of conversion to mammalian target of rapamycin inhibitors is crucial in liver transplant recipients with impaired renal function at transplantation.

Schleicher C, Palmes D, Utech M, Bonrath E, Senninger N, Schmidt H, Wolters H.

Transplant Proc. 2010 Sep;42(7):2572-5. doi: 10.1016/j.transproceed.2010.05.159.

PMID:
20832546
8.

Resolution of sirolimus-induced pneumonitis after conversion to everolimus.

Rehm B, Keller F, Mayer J, Stracke S.

Transplant Proc. 2006 Apr;38(3):711-3.

PMID:
16647451
9.

Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.

Grgic T, Mis L, Hammond JM.

Ann Pharmacother. 2011 Jan;45(1):78-83. doi: 10.1345/aph.1M288. Epub 2010 Dec 21. Review.

PMID:
21177421
10.

Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.

Gabardi S, Baroletti SA.

Pharmacotherapy. 2010 Oct;30(10):1044-56. doi: 10.1592/phco.30.10.1044. Review.

PMID:
20874042
11.

Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.

Molas-Ferrer G, Soy-Muner D, Anglada-Martínez H, Riu-Viladoms G, Estefanell-Tejero A, Ribas-Sala J.

Nefrologia. 2013;33(3):297-300. doi: 10.3265/Nefrologia.pre2013.Jan.11439. Review. English, Spanish.

12.

Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.

Wüthrich RP, Kistler AD, Serra AL.

Transplant Proc. 2010 Nov;42(9 Suppl):S44-6. doi: 10.1016/j.transproceed.2010.07.008. Review.

PMID:
21095452
13.

Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview.

Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L.

Transpl Int. 2007 Apr;20(4):305-11. Review.

14.

Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma.

Tobinai K, Ogura M, Maruyama D, Uchida T, Uike N, Choi I, Ishizawa K, Itoh K, Ando K, Taniwaki M, Shimada N, Kobayashi K.

Int J Hematol. 2010 Nov;92(4):563-70. doi: 10.1007/s12185-010-0707-5. Epub 2010 Oct 23.

PMID:
20972652
15.

Everolimus- and temsirolimus-associated enteritis: report of three cases.

Parithivel K, Ramaiya N, Jagannathan JP, O'Regan K, Krajewski K, Fisher D, Choueiri TK, Jacobsen E.

J Clin Oncol. 2011 May 10;29(14):e404-6. doi: 10.1200/JCO.2010.33.5984. Epub 2011 Feb 28. No abstract available.

PMID:
21357780
16.

Common occurrence of everolimus-associated aphthous stomatitis in Japanese heart transplant recipients.

Sasaoka T, Kato TS, Oda N, Wada K, Komamura K, Asakura M, Hashimura K, Ishibashi-Ueda H, Nakatani T, Isobe M, Kitakaze M.

Transplant Proc. 2010 Nov;42(9):3700-3. doi: 10.1016/j.transproceed.2010.06.023.

PMID:
21094841
17.

Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report.

De Simone P, Petruccelli S, Precisi A, Carrai P, Doria R, Menichetti F, Filipponi F.

Transplant Proc. 2007 Dec;39(10):3500-1.

PMID:
18089420
18.

Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.

Nozawa M, Ohzeki T, Tamada S, Hongo F, Anai S, Fujimoto K, Miki T, Nakatani T, Fukasawa S, Uemura H.

Int J Clin Oncol. 2015 Aug;20(4):790-5. doi: 10.1007/s10147-014-0764-5. Epub 2014 Oct 25.

PMID:
25342378
19.

Sirolimus-induced pneumonitis following liver transplantation.

Roberts RJ, Wells AC, Unitt E, Griffiths M, Tasker AD, Allison ME, Bradley JA, Watson CJ.

Liver Transpl. 2007 Jun;13(6):853-6.

20.

Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.

Paoletti E, Cannella G.

Transplant Proc. 2010 Nov;42(9 Suppl):S41-3. doi: 10.1016/j.transproceed.2010.07.007. Review.

PMID:
21095451

Supplemental Content

Support Center